Gastroparesis, also known as stomach paralysis, occurs when the stomach muscles fail to function properly, causing severe and debilitating symptoms, such as: Chronic nausea and vomiting Extreme bloating and abdominal pain Severe dehydration and malnutrition Inability to properly digest food Dependence on feeding tubes or hospitalization For many patients, these complications require ongoing medical treatment, including hospital stays, invasive procedures, and long-term dietary restrictions
Rather than further investigating the nearly 20,000 adverse events reported to the FDA, Novo Nordisk pumped billions into advertising and celebrity endorsers speaking out on the weight loss benefits, producing billions of dollars in revenue while users continue to report new digestive illnesses
The regulatory landscape continues to evolve
Valine-Citrulline (VCit) is a prominent enzymatic unit in approved ADCs, designed for selective hydrolysis by lysosomal proteases at the amide bond between citrulline and the p-aminobenzyl carbamate (PABC) spacer (Figure 5)
Additionally, Halden et al
